Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook
Molecular Pharmaceutics · 02.12.2024 · 21 (12) · 5909-5928
DOI: 10.1021/acs.molpharmaceut.4c00848 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 13.11.2024. Verfasst von Yongshun Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Molecular Imaging, Cell Adhesion Molecules, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Peking University First Hospital.
Abstract (Originalsprache)
Trophoblast cell surface antigen 2 (Trop2), a transmembrane glycoprotein, plays a dual role in physiological and pathological processes. In healthy tissues, Trop2 facilitates development and orchestrates intracellular calcium signaling. However, its overexpression in numerous solid tumors shifts its function toward driving cell proliferation and metastasis, thus leading to a poor prognosis. The clinical relevance of Trop2 is underscored by its utility as both a biomarker for diagnostic imaging and a target for therapy. Notably, the U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan (SG), a novel Trop2-targeted agent, for treating triple-negative breast cancer (TNBC) and refractory urothelial cancer, highlighting the significance of Trop2 in clinical oncology. Molecular imaging, a powerful tool for visualizing and quantifying biological phenomena at the molecular and cellular levels, has emerged as a critical technique for studying Trop2. This approach encompasses various modalities, including optical imaging, positron emission tomography (PET), single photon emission computed tomography (SPECT), and targeted antibodies labeled with radioactive isotopes. Incorporating Trop2-targeted molecular imaging into clinical practice is vital for the early detection, prognostic assessment, and treatment planning of a broad spectrum of solid tumors. Our review captures the latest progress in Trop2-targeted molecular imaging, focusing on both diagnostic and therapeutic applications across diverse tumor types, including lung, breast, gastric, pancreatic, prostate, and cervical cancers, as well as salivary gland carcinomas. We critically evaluate the current state by examining the relevant applications, diagnostic accuracy, therapeutic efficacy, and inherent limitations. Finally, we analyze the challenges impeding widespread clinical application and offer insights into strategies for advancing the field, thereby guiding future research endeavors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
- Departments of Radiology and Medical Physics, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
Förderung
- NCI NIH HHS
- National Cancer Institute
- Peking University First Hospital
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- National Natural Science Foundation of China
- University of Wisconsin-Madison
- Beijing Science Foundation for Distinguished Young Scholars
Zitieren
APA
Liu, Y., Huang, W., Saladin, R. J., Hsu, J. C., Cai, W., & Kang, L. (2024). Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook. Molecular Pharmaceutics, 21(12), 5909-5928. https://doi.org/10.1021/acs.molpharmaceut.4c00848
Vancouver
Liu Y, Huang W, Saladin RJ, Hsu JC, Cai W, Kang L. Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook. Molecular Pharmaceutics. 2024;21(12):5909-5928. doi:10.1021/acs.molpharmaceut.4c00848
BibTeX
@article{Liu2024,
author = {Liu, Yongshun and Huang, Wenpeng and Saladin, Rachel J and Hsu, Jessica C and Cai, Weibo and Kang, Lei},
title = {Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {12},
pages = {5909--5928},
doi = {10.1021/acs.molpharmaceut.4c00848}
}
EUVIMED